Topic List : Cardiovascular Health
Three elected to National Academy of Medicine
Hongjie Dai, Julie Parsonnet and Joseph Wu are among the 90 regular members and 10 international members elected this year to the academy, which aims to provide independent, scientifically informed analysis and recommendations on health issues.
Invasive heart treatments often needless
A large, international study led by Stanford and New York University found that invasive procedures are no better than medications and lifestyle advice at treating heart disease that's severe but stable.
Through Apple Heart Study, Stanford Medicine researchers show wearable technology can help detect atrial fibrillation
Study shows that Apple Watch app can identify heart rhythm irregularities, which can help catch atrial fibrillation.
Shape-shifting cells protect in artery disease
Stanford scientists and their collaborators have discovered the protective role played by identity-morphing cells — and the gene behind them — in atherosclerosis, according to a new study.
Possible drug target for cardiomyopathy
Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.
Stanford-led team awarded $10 million
Stanford scientists will direct a multidisciplinary, multi-institutional team focused on understanding in detail how tiny mutations in a protein, myosin, can cause the classic features of cardiomyopathy.
Gene networks and heart failure
A Stanford-led research team has mapped out a network of gene activity before and after heart failure to better understand how heart health declines.
E-cigarette flavorings harm blood vessel cells
E-cigarette flavorings damage human blood vessel cells grown in the lab even in the absence of nicotine, Stanford researchers and their colleagues found. Cinnamon and menthol flavors were particularly harmful.
Drug reduces kidney failure in diabetics
Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.
Identifying familial hypercholesterolemia
Stanford scientists and their collaborators have devised an algorithm to predict the risk of a disease that, untreated, can lead to heart attack or stroke.